AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
154 hedge funds and large institutions have $1.36B invested in AMAG Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 38 increasing their positions, 47 reducing their positions, and 10 closing their positions.
509% more call options, than puts
Call options by funds: $914K | Put options by funds: $150K
440% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 10
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
61% more capital invested
Capital invested by funds: $847M → $1.36B (+$515M)
36% more funds holding
Funds holding: 113 → 154 (+41)
19% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$35.6M |
| 2 |
GCM
Greywolf Capital Management
Purchase,
New York
|
+$31.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$23.9M |
| 4 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$20.5M |
| 5 |
CGM
Capital Growth Management
Boston,
Massachusetts
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$60.3M |
| 2 |
BC
Broadfin Capital
New York
|
-$33.9M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$15M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$8.68M |
| 5 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
-$8.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NES
151
New England Securities
New York
| $4K | – | – | – |
|
|
PIM
152
Parasol Investment Management
Westmont,
Illinois
| $4K | – | – | – |
|
153
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $2K | +$1.55K | +43 | New |
|
154
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $593 | -$23.3K | -644 | -4% |
|
|
VAM
155
Visium Asset Management
New York
| – | -$60.3M | -1,890,200 | Closed |
|
|
JGC
156
J. Goldman & Co
New York
| – | -$3.27M | -102,500 | Closed |
|
157
Norges Bank
Oslo,
Norway
| – | -$2.45M | -76,824 | Closed |
|
158
Jane Street
New York
| – | -$1.62M | -50,902 | Closed |
|
|
BCM
159
BBT Capital Management
Fort Worth,
Texas
| – | -$753K | -23,612 | Closed |
|
|
VKH
160
Virtu KCG Holdings
New York
| – | -$339K | -10,626 | Closed |
|
|
PAM
161
Panagora Asset Management
Boston,
Massachusetts
| – | -$300K | -9,414 | Closed |
|
|
OC
162
Oppenheimer & Co
New York
| – | -$243K | -7,616 | Closed |
|
|
PCM
163
Prelude Capital Management
New York
| – | -$198K | -6,200 | Closed |
|
164
Group One Trading
Chicago,
Illinois
| – | -$54.6K | -1,510 | Closed |
|
AMAG Hedge Fund Activity: Q4 2014 in Review
154 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q4 2014, worth a combined $1.36B — up 61% from $847M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new AMAG positions and 10 closed out — a net gain of 44 holders — while 38 added to existing stakes and 47 trimmed.
The largest buyer was Wells Fargo, adding an estimated $35.6M. The largest seller was Visium Asset Management, exiting entirely with an estimated $60.3M sold.
- 154 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q4 2014, up from 113 in Q3 2014.
- Funds reported $1.36B of AMAG Pharmaceuticals stock for Q4 2014, up 61% quarter-over-quarter.
- 54 funds opened new AMAG Pharmaceuticals positions in Q4 2014 and 10 closed out, a net change of +44 holders.
- The largest AMAG Pharmaceuticals buyer in Q4 2014 was Wells Fargo, an estimated $35.6M added.
- The largest AMAG Pharmaceuticals seller in Q4 2014 was Visium Asset Management, an estimated $60.3M sold.
Based on aggregated 13F filings for Q4 2014.